Melius Pharma is a Swedish clinical-stage pharmaceutical company developing a therapy for Th2-associated refractory chronic cough (RCC), a large and underserved condition with significant patient burden and no effective targeted treatments.ME-015 modulates Th2-driven airway inflammation, a clinically validated driver of cough hypersensitivity in a biomarker-defined patient subgroup identifiable via FeNO and eosinophils. This enables a precision medicine approach with higher probability of clinical success.
The program is de-risked by >25 years of safety data from Japan, with no formulation or CMC risk, while offering NCE status outside Japan and global rights.A biomarker-enriched Phase 2a study is planned to demonstrate proof-of-concept using objective cough endpoints, supporting a focused market entry followed by expansion into broader Th2-associated cough indications.
